Infliximab induces downregulation of the IL-12/IL-23 axis in 6-sulfo-LacNac (slan)+ dendritic cells and macrophages

Journal of Allergy and Clinical Immunology

Volumn 132, Issue 5, 2013, Pages

  Brunner, Patrick M ^a   Koszik, Frieder ^a   Reininger, Bärbel ^a   Kalb, Madeleine L ^a   Bauer, Wolfgang ^a   Stingl, Georg ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

Author keywords

6 sulfo LacNac; IL 12p40; myeloid dendritic cells; Psoriasis; TNF

Indexed keywords

ADALIMUMAB; CD14 ANTIGEN; CD163 ANTIGEN; CD45 ANTIGEN; ETANERCEPT; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR BETA1; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; LEUKOCYTE; MACROPHAGE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

EID: 84887018585     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2013.05.036     Document Type: Article

References (50)

1. E. Christophers Psoriasis - epidemiology and clinical spectrum Clin Exp Dermatol 26 2001 314 320
2. F.O. Nestle, D.H. Kaplan, and J. Barker Psoriasis N Engl J Med 361 2009 496 509
3. C.E. Griffiths, and J.N. Barker Pathogenesis and clinical features of psoriasis Lancet 370 2007 263 271
4. K. Reich The concept of psoriasis as a systemic inflammation: implications for disease management J Eur Acad Dermatol Venereol 26 suppl 2 2012 3 11
5. B.B. Davidovici, N. Sattar, J.C. Prinz, L. Puig, P. Emery, and J.N. Barker Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions J Invest Dermatol 130 2010 1785 1796
6. A. Hänsel, C. Günther, J. Ingwersen, J. Starke, M. Schmitz, and M. Bachmann Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses J Allergy Clin Immunol 127 2011 787 794 e1-9
7. L.C. Zaba, J. Fuentes-Duculan, N.J. Eungdamrong, M.V. Abello, I. Novitskaya, and K.C. Pierson Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells J Invest Dermatol 129 2009 79 88
8. K. Reich, A.D. Burden, J.N. Eaton, and N.S. Hawkins Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials Br J Dermatol 166 2012 179 188
9. M. Kriegler, C. Perez, K. DeFay, I. Albert, and S.D. Lu A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF Cell 53 1988 45 53
10. D. Tracey, L. Klareskog, E.H. Sasso, J.G. Salfeld, and P.P. Tak Tumor necrosis factor antagonist mechanisms of action: a comprehensive review Pharmacol Ther 117 2008 244 279
11. L. Ackermann, and I.T. Harvima Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-alpha and their degranulation is associated with expression of ICAM-1 in the epidermis Arch Dermatol Res 290 1998 353 359
12. L.M. Austin, M. Ozawa, T. Kikuchi, I.B. Walters, and J.G. Krueger The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients J Invest Dermatol 113 1999 752 759
13. C. Johansen, A.T. Funding, K. Otkjaer, K. Kragballe, U.B. Jensen, and M. Madsen Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2 J Immunol 176 2006 1431 1438
14. M. Kristensen, C.Q. Chu, D.J. Eedy, M. Feldmann, F.M. Brennan, and S.M. Breathnach Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor Clin Exp Immunol 94 1993 354 362
15. B.J. Nickoloff, G.D. Karabin, J.N. Barker, C.E. Griffiths, V. Sarma, and R.S. Mitra Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis Am J Pathol 138 1991 129 140
16. S. Terajima, M. Higaki, Y. Igarashi, T. Nogita, and M. Kawashima An important role of tumor necrosis factor-alpha in the induction of adhesion molecules in psoriasis Arch Dermatol Res 290 1998 246 252
17. M.A. Lowes, F. Chamian, M.V. Abello, J. Fuentes-Duculan, S.L. Lin, and R. Nussbaum Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a) Proc Natl Acad Sci U S A 102 2005 19057 19062
18. J. Fuentes-Duculan, M. Suarez-Farinas, L.C. Zaba, K.E. Nograles, K.C. Pierson, and H. Mitsui A subpopulation of CD163-positive macrophages is classically activated in psoriasis J Invest Dermatol 130 2010 2412 2422
19. T. Horiuchi, H. Mitoma, S. Harashima, H. Tsukamoto, and T. Shimoda Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents Rheumatology (Oxford) 49 2010 1215 1228
20. H. Mitoma, T. Horiuchi, H. Tsukamoto, Y. Tamimoto, Y. Kimoto, and A. Uchino Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab Arthritis Rheum 58 2008 1248 1257
21. J. Gerspach, A. Gotz, G. Zimmermann, C. Kolle, H. Bottinger, and M. Grell Detection of membrane-bound tumor necrosis factor (TNF): an analysis of TNF-specific reagents Microsc Res Tech 50 2000 243 250
22. L.C. Zaba, J. Fuentes-Duculan, R.M. Steinman, J.G. Krueger, and M.A. Lowes Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages J Clin Invest 117 2007 2517 2525
23. K.P. MacDonald, D.J. Munster, G.J. Clark, A. Dzionek, J. Schmitz, and D.N. Hart Characterization of human blood dendritic cell subsets Blood 100 2002 4512 4520
24. K. Schäkel, R. Kannagi, B. Kniep, Y. Goto, C. Mitsuoka, and J. Zwirner 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells Immunity 17 2002 289 301
25. J. Cros, N. Cagnard, K. Woollard, N. Patey, S.Y. Zhang, and B. Senechal Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors Immunity 33 2010 375 386
26. K.L. Wong, W.H. Yeap, J.J. Tai, S.M. Ong, T.M. Dang, and S.C. Wong The three human monocyte subsets: implications for health and disease Immunol Res 53 2012 41 57
27. L. Ziegler-Heitbrock, P. Ancuta, S. Crowe, M. Dalod, V. Grau, and D.N. Hart Nomenclature of monocytes and dendritic cells in blood Blood 116 2010 e74 e80
28. K.L. Wong, J.J. Tai, W.C. Wong, H. Han, X. Sem, and W.H. Yeap Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets Blood 118 2011 e16 e31
29. A.M. Zawada, K.S. Rogacev, B. Rotter, P. Winter, R.R. Marell, and D. Fliser SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset Blood 118 2011 e50 e61
30. K. Schäkel, M. von Kietzell, A. Hansel, A. Ebling, L. Schulze, and M. Haase Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes Immunity 24 2006 767 777
31. T. Döbel, A. Kunze, J. Babatz, K. Trankner, A. Ludwig, and M. Schmitz FcgammaRIII (CD16) equips immature 6-sulfo LacNAc-expressing dendritic cells (slanDCs) with a unique capacity to handle IgG-complexed antigens Blood 121 2013 3609 3618
32. B. Hunyady, K. Krempels, G. Harta, and E. Mezey Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining J Histochem Cytochem 44 1996 1353 1362
33. C. Günther, J. Starke, N. Zimmermann, and K. Schäkel Human 6-sulfo LacNAc (slan) dendritic cells are a major population of dermal dendritic cells in steady state and inflammation Clin Exp Dermatol 37 2012 169 176
34. N. van der Laan, L.F. de Leij, W. Buurman, W. Timens, and H.J. ten Duis Tumor necrosis factor alpha (TNFalpha) in human skin: a comparison of different antibodies for immunohistochemistry Arch Dermatol Res 293 2001 226 232
35. Z. Kaymakcalan, P. Sakorafas, S. Bose, S. Scesney, L. Xiong, and D.K. Hanzatian Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor Clin Immunol 131 2009 308 316
36. K. Schäkel, E. Mayer, C. Federle, M. Schmitz, G. Riethmuller, and E.P. Rieber A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes Eur J Immunol 28 1998 4084 4093
37. M. Rossol, S. Kraus, M. Pierer, C. Baerwald, and U. Wagner The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population Arthritis Rheum 64 2012 671 677
38. E.J. Armstrong, C.T. Harskamp, and A.W. Armstrong Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies J Am Heart Assoc 2 2013 e000062
39. T. Arora, R. Padaki, L. Liu, A.E. Hamburger, A.R. Ellison, and S.R. Stevens Differences in binding and effector functions between classes of TNF antagonists Cytokine 45 2009 124 131
40. C.E. Zielinski, F. Mele, D. Aschenbrenner, D. Jarrossay, F. Ronchi, and M. Gattorno Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta Nature 484 2012 514 518
41. E.G. Harper, C. Guo, H. Rizzo, J.V. Lillis, S.E. Kurtz, and I. Skorcheva Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis J Invest Dermatol 129 2009 2175 2183
42. C.E. Griffiths, B.E. Strober, P. van de Kerkhof, V. Ho, R. Fidelus-Gort, and N. Yeilding Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis N Engl J Med 362 2010 118 128
43. E.V. Acosta-Rodriguez, G. Napolitani, A. Lanzavecchia, and F. Sallusto Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells Nat Immunol 8 2007 942 949
44. K. Ghoreschi, A. Laurence, X.P. Yang, C.M. Tato, M.J. McGeachy, and J.E. Konkel Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling Nature 467 2010 967 971
45. G. Stary, I. Klein, M.C. Brüggen, S. Kohlhofer, P.M. Brunner, and D. Spazierer Host defense mechanisms in secondary syphilitic lesions: a role for IFN-gamma-/IL-17-producing CD8+ T cells? Am J Pathol 177 2010 2421 2432
46. B. Hunyady, K. Krempels, G. Harta, and E. Mezey Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining J Histochem Cytochem 44 1996 1353 1362
47. C. Bangert, B.E. Strober, M. Cork, J.P. Ortonne, T. Luger, and T. Bieber Clinical and cytological effects of pimecrolimus cream 1% after resolution of active atopic dermatitis lesions by topical corticosteroids: a randomized controlled trial Dermatology 222 2011 36 48
48. M.L. Kalb, A. Glaser, G. Stary, F. Koszik, and G. Stingl TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-alpha-mediated antitumor reactivity J Immunol 188 2012 1583 1591
49. S.R. Feldman, and G.G. Krueger Psoriasis assessment tools in clinical trials Ann Rheum Dis 64 suppl 2 2005 ii65 ii73
50. S. Amatschek, E. Kriehuber, W. Bauer, B. Reininger, P. Meraner, and A. Wolpl Blood and lymphatic endothelial cell-specific differentiation programs are stringently controlled by the tissue environment Blood 109 2007 4777 4785